05.05.2021 • News

Total and Gevo Advance Renewable Isoamylene Work

Total’s specialty chemical additives subsidiary Total Cray Valley and US renewables company Gevo have completed the first phase of their Joint Development Agreement (JDA) to upgrade fusel oils into renewable isoamylene.

“We were very satisfied with the results of pilot tests during Phase 1. Gevo’s technology was found to be robust and flexible, and the initial economic assessment shows potential for a profitable business,” said Valérie Goff, senior vice president at Total.

Signed in 2020, the JDA is centered on Gevo’s chemical-based catalytic technology, which selectively converts low-value fusel oils, a mixture of alcohols that are byproducts from fermentation processes such as ethanol or isobutanol production, into higher-value renewable chemicals, for example isoprene, ketones, aldehydes or olefins – in this case isoamylene.

Cray Valley uses isoamylene as a raw material in manufacturing resins. Isoamylene also has a diverse set of other uses, including in pesticides, flavors and fragrances, pharmaceuticals, healthcare products, adhesives, antioxidants and UV stabilizers.

The companies are now seeking to advance to phase two of the JDA, which will allow for Gevo’s technology to be scaled up to commercial production.

Paul Bloom, Gevo’s chief technology and innovation officer, said that every pound of biobased isoamylene made and used in durable products like resins is the equivalent of sequestering 2.5 pounds of biogenic CO2 from the atmosphere.

Author: Elaine Burridge, Freelance Journalist

Total Cray Valley and Gevo have completed the first phase of their Joint...
Total Cray Valley and Gevo have completed the first phase of their Joint Development Agreement (JDA) to upgrade fusel oils into renewable isoamylene. The companies are now seeking to advise to phase 2 of the JDA, which will allow for Gevo’s technology to be scaled up to demonstration scale. (c) Total

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

most read